Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the us: A literature review

PharmacoEconomics

Volumn 29, Issue 6, 2011, Pages 461-474

  Zhang, Bin ^a   Donga, Prina Z ^a   Corral, Mitra ^b   Sasane, Medha ^b   Miller, Jeffrey D ^a   Pashos, Chris L ^a,c  

^a Abt Bio Pharma Solutions Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Beta thalassaemia, contributory factors; Cost effectiveness; Deferasirox, therapeutic use; Deferoxamine, therapeutic use; Iron chelating agents, therapeutic use; Iron overload, treatment; Myelodysplastic syndromes, contributory factors; Sickle cell anaemia, contributory factors

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

BETA THALASSEMIA; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEALTH CARE COST; HEMOSIDEROSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SICKLE CELL ANEMIA; UNITED STATES;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; UNITED STATES;

EID: 79956133784     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11589250-000000000-00000     Document Type: Review

References (42)

1. Dipiro J, Talbert R, Yee G, et al. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill Medical, 2002.
2. Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassemia. 2nd rev. ed. Nicosia: Thalassemia International Federation, 2010.
3. National Cancer Institute. Myelodysplastic syndromes treat- ment (PDQ®): general information about myelodysplastic syndromes [online]. Available from URL: http://www.nci. nih.gov/cancertopics/pdq/treatment/ myelodysplastic/health professional/ [Accessed 2009 Jul 2].
4. Exjade® (deferasirox) [package insert]. East Hanover (NJ): Novartis Pharmaceutical Corporation, 2010.
5. Desferal® (deferoxamine) [package insert]. East Hanover (NJ): Novartis Pharmaceutical Corporation, 2008.
6. WHO. Genes and human disease: monogenic diseases [online]. Available from URL: http://www.who.int/genomics/public/ geneticdiseases/en/index2.html/ [Accessed 2011 Mar 16].
7. Cunningham MJ, Nathan DG. New developments in iron chelators. Curr Opin Hematol 2005; 12: 129-34. (Pubitemid 40315697)
8. Borgna-Pignatti C, Rugolotto S, De SP, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93. (Pubitemid 39390442)
9. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 47-61.
10. Wayne AS, Kevy SV, Nathan DG. Transfusion manage- ment of sickle cell disease. Blood 1993; 81: 1109-23. (Pubitemid 23067344)
11. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1-16. (Pubitemid 40299770)
12. Malcovati L, Porta MG, Pascutto C, et al. Prognostic fac- tors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-603. (Pubitemid 46291823)
13. Fung EB, Harmatz P, Milet M, et al. Morbidity and mor- tality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 2007; 82: 255-65. (Pubitemid 46564319)
14. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80: 70-4. (Pubitemid 41254272)
15. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with mye-lodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009; 25: 139-47.
16. US Bureau of Labor Statistics. Medical care component of consumer price index, 2009 [online]. Available from URL: http://www.bls.gov/cpi/cpid09av.pdf [Accessed 2011 Mar 16].
17. Delea TE, Thomas SK, Baladi JF, et al. Utilization and costs of deferoxamine in patients with thalassemia, sickle cell disease, or myelodysplastic syndrome receiving transfusions [abstract no. 5583]. 47th American Society of He-matology Annual Meeting and Exposition; 2005 Dec 10-13; Atlanta (GA).
18. Delea TE, Hagiwara M, Thomas SK, et al. Outcomes, uti- lization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol 2008; 83: 263-70. (Pubitemid 351458002)
19. Renfroe LJ, Forbes P, Braunstein J, et al. Relationship of transfusion and iron-related complications to cost of care in thalassemia [abstract no. 2240]. 47th American Society of Hematology Annual Meeting and Exposition; 2005 Dec 10-13; Atlanta (GA).
20. Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000; 96: 2369-72.
21. Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and eco- nomic burden of infused iron chelation therapy in the United States. Transfusion 2007; 47: 1820-9. (Pubitemid 47438548)
22. Greenberg PL, Cosler LE, Ferro SA, et al. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008; 6 (9): 942-53.
23. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29: 909-17. (Pubitemid 47241173)
24. Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008; 24: 1905-17.
25. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient- reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfu-sional hemosiderosis: substudy of a randomized open-label phase II trial. Acta Haematol 2008; 119: 133-41. (Pubitemid 351896547)
26. Delea T, Sofrygin O, Thomas S, et al. Cost-effectiveness of once-daily oral therapy with deferasirox in transfusion-dependent thalassemic patients [abstract no. 1341]. 47th American Society of Hematology Annual Meeting and Exposition; 2005 Dec 10-13; Atlanta (GA).
27. Delea TE, Sofrygin O, Thomas SK, et al. Costs and con- sequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia [abstract no. 7637]. ISPOR 11th Annual International Meeting; 2006 May 20-24; Philadelphia (PA).
28. Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalas-saemia patients: US healthcare system perspective. Pharmaco-economics 2007; 25 (4): 329-42. (Pubitemid 46607383)
29. Delea T, Sofrygin O, Baladi JF, et al. Chelation therapy with deferasirox versus deferoxamine in transfusion-dependent sickle-cell disease: a cost effectiveness analysis from the US perspective. 11th Congress of the European Hematology Association; 2006 Jun 15-18; Amsterdam.
30. Migliaccio-Walle K, Baladi JF. Economic implications of iron chelation in patients with refractory anemia related to myelodysplastic syndrome [abstract no. 18118]. ISPOR 11th Annual European Congress; 2008 Nov 8-11; Athens.
31. Delea T, Baladi JF, Thomas S, et al. Cost-effectiveness of chelation therapy with deferasirox versus deferoxamine in transfusion-dependent myelodysplastic syndrome. 11th Congress of the European Hematology Association; 2006 Jun 15-18; Amsterdam.
32. Bozkaya D, Migliaccio-Walle K, Baladi JF. Impact of management of iron overload in patients with myelodys-plastic syndromes [abstract no. 1308]. 50th Annual American Society of Hematology; 2008 Dec 6-9; San Francisco (CA).
33. Hirth RA, Chernew ME, Miller E. Willingness to pay for a quality adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-42. (Pubitemid 30479101)
34. Ubel PA, Hirth RA, Chernew ME. What is the price of life and why doesn't it increase at the rate of inflation? Arch Int Med 2003; 163: 1637-41. (Pubitemid 36898950)
35. McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009; 13: iii-xi, 1.
36. Tolley K, Oyee J, Knight H, et al. UK community-derived utilities using time trade-off for oral versus subcutaneous iron chelation therapy for the treatment of chronic iron overload [abstract no. 14941]. ISPOR 10th Annual European Congress; 2007 Oct 20-23; Dublin.
37. Osborne RH, DeAbreu Lourenco R, Dalton A, etal. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007; 10: 451-6. (Pubitemid 350013265)
38. Payne KA, Rofail D, Baladi JF, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther 2008; 25: 725-42.
39. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron con- centration combined with longterm monitoring of serum ferritin to predict complications of iron overload in tha-lassaemia major. Br J Haematol 2000; 110: 971-7.
40. Kim J, Kim Y. Economic evaluation of oral deferasirox versus infusional deferoxamine [abstract no. 17525]. ISPOR 3rd Asia Pacific Congress; 2008 Sep 7-9; Seoul.
41. Ladis V, Chouliaras G, Berfousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445-50. (Pubitemid 43031054)
42. Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag 2009; 5: 857-68